

Appendix

Doing more does not mean doing better: the FADOI contribution to the *Slow Medicine* program for a sustainable and wise healthcare system

Luigi Lusiani, Roberto Frediani, Roberto Nardi, Andrea Fontanella, Mauro Campanini

The ten practices with the highest degree of risk of non-appropriateness in

Internal Medicine. The FADOI endorsement

1	<p>Do not prescribe acid suppressant therapy in order to prevent stress ulcers in hospitalized patients, unless there is a high risk of bleeding.</p> <p>According to the international guidelines, the pharmacological prophylaxis of the peptic stress ulcers with antagonists of the H₂ receptors or proton pump inhibitors (PPI) is not indicated outside the intensive care setting. Even the term <i>gastric protection</i> should be avoided in this context, because it emphasizes the beneficial (obviously desirable) action, while masking the adverse effects and the possible harms. In particular, the PPI, largely used for prevention purposes in Italy, enhance the susceptibility to communitary pneumonias and to <i>Chlostridium difficile</i> infections. Even if thought for a limited period of time during a hospital stay, their prescription tends to persist indefinitely outside the hospital, with a relevant impact in terms of pharmacy expenditures.</p>
2	<p>Do not treat a bacteriuria with antibiotics in elderly patients without urinary symptoms.</p> <p>An asymptomatic bacteriuria should be managed conservatively. In elderly people, a bacteriuria is not necessarily harmful, while antibiotics are not obviously beneficial: often, they bring about undesirable effects, such as specific adverse reactions and undue selective pressure over the colonizing bacteria (especially enteric), with the development of resistant species. Screening and subsequent treatment of asymptomatic bacteriuria is justified only before urological procedures with anticipated mucosal bleeding. In 30% of asymptomatic subjects, a bacteriuria is not confirmed by a second examination.</p>
3	<p>Do not recommend percutaneous feeding tubes in advanced dementia; prefer oral assisted feeding instead.</p> <p>In advanced dementia, the use of percutaneous feeding tubes does not increase survival, does not lower the risk of aspiration pneumonias, does not improve the healing of existing pressure ulcers (instead, it increases their risk); it augments physiological stress, the need for physical containment and sedation, the risk of water overcharge, diarrhea, abdominal pain, local complications. The oral assisted feeding improves the nutritional status. However, in the end of life stage, nutrition should be focused on comfort and human relationship rather than on nutritional objectives.</p>
4	<p>Do not repeat chemistry testing in the face of clinical and laboratory stability.</p> <p>In the general wards, the patients are often submitted to repetitive draws of blood in the short terms, for redundant chemistry testing. Altered laboratory results often require controls, even though the original request was futile, and this amplifies the phenomenon. The anemia induced during hospitalization as a consequence of frequent draws tends to be underestimated, and this may become a problem in specific clinical settings. Attempts to</p>

	<p>introduce back-control in laboratory orders, based on <i>reflex</i> systems, incompatibility with previous results and automatic temporal filters are under way. However, it is part of the responsibility of the orderer to discern what is aimlessly repetitive, also through a better cooperation with the laboratory. Obviously, futile examinations produce wasting.</p>
5	<p>Do not transfuse red blood cells for arbitrary Hb levels, without symptoms of active coronary artery disease, heart failure, stroke.</p> <p>In chronic anemia states, a sparing transfusion policy is recommended, even in hospitalized patients. In general, a decision to transfuse should be considered starting from Hb levels of 6 g/dl in young patients with acute anemia, 7 in the great majority of patients, 8 in patients with previous cardiovascular diseases, 9 in critical patients. However, a decision should be based also on many factors that condition the clinical state of a patient, and the necessity of oxygenate underperfused organs. More liberal indications should be adopted in patients with symptoms of active coronary artery disease, heart failure and stroke. However, also in this kind of patients the benefit of Hb above 10 is uncertain. Unnecessary transfusions expose to undue risk of adverse events not counterbalanced by adjunctive benefits, and determine wasting.</p>
6	<p>Do not use benzodiazepines in elderly patients as a first choice for insomnia, agitation, and delirium.</p> <p>Elderly people assuming hypnotics (especially benzodiazepines) experience car accidents and falls with femur fractures and consequent hospitalization, more often than others. Also the hospitalized patients assuming benzodiazepines risk falls and their consequences, due to depressed alertness, motor deficits and cognitive impairment. The use of these drugs should be limited to alcohol withdrawal and anxious states. When requested, low dosage, short half-life and intermittent use should be preferred, and prolonged use should be submitted to frequent re-evaluation. In case of agitation and delirium, other drug should be preferred.</p>
7	<p>Do not delay palliative cares in the dying patients.</p> <p>The quality of care offered to the dying patients in hospital is far from being optimal, mainly due to the fact that, because of organization and medicine attitude, in the general wards one tends to maintain standard therapeutic and diagnostic options, typically addressed to acute diseases, disregarding the real needs of a patient. This determines an insufficient control of the key symptoms that characterize the end stage (pain, dyspnea, agitation, respiratory secretions, <i>etc.</i>), with a negative impact on patients, caregivers and staff members themselves. The adoption of specifically conceived care-pathways improves symptom relief and confers dignity to end-of-life, without accelerating death (on the contrary, prolonging life in selected patients).</p>
8	<p>Do not routinely prescribe lipid-lowering drugs in patients with a limited life expectancy.</p> <p>Up to one-third of the population aged between 75 and 85 years assumes lipid-lowering drugs (mainly statins) for primary or secondary prevention purposes. However, the concept that high LDL-cholesterol and/or low HDL in elderly people are as important cardiovascular</p>

	<p>risk factors as in younger ages is controversial, being extrapolated; indeed, in the very old people, low LDL-cholesterol correlates with an increased mortality. Above 85 years, the risk/benefit ratio of statins is not obviously a favorable one because, while life expectancy decreases, the incidence of adverse effects (muscular damage, neuropathy, cognitive derangement, falls) becomes relatively greater. In the face of a limited life expectancy (<i>i.e.</i>, less than 10 years), starting a therapy with statins is not evidence based, maintaining it, is questionable.</p>
9	<p>Do not use non-steroid anti-inflammatory drugs (NSAID) in subjects with arterial hypertension, heart failure, renal insufficiency from any cause, including diabetes.</p>
	<p>NSAID are largely used for muscle, bone and joint pain, but are associated with important cardiovascular, renal and hematological adverse effects, especially in elderly people. They may determine a blunted response to the antihypertensive drugs, water retention and worsening of the renal function in patients with high blood pressure, heart failure and chronic kidney disease from any cause, including diabetes. The most recent guidelines recommend to limit NSAID for the pain control in patients affected by such diseases, and to prefer paracetamol, tramadol and short-lived opioids as an alternative, as far as possible.</p>
10	<p>Do not perform PET/CT for cancer screening in healthy subjects.</p>
	<p>The probability to detect a tumor with such method in asymptomatic subjects is lower than 1%. In many cases, the diagnoses deal with indolent tumors (<i>i.e.</i>, low grade lymphomas), which do not benefit from early therapy, or far advanced and untreatable (although silent) tumors (<i>i.e.</i>, pancreatic cancer). False positive results predominate (especially in the head-neck region), bringing about adjunctive examinations and unnecessary (so harmful) biopsies and surgical procedures. Like all the other diagnostic methods, PET/TC must be used in front of clear questions and definite clinical settings.</p>

How this list was created

After its adhesion to the Slow Medicine program, the FADOI was asked to contribute with a list of ten recommendations.

In early 2014, the National FADOI Council committed 2 of its component to elaborate a questionnaire containing a selection of the recommendations already published by Choosing Wisely® (270 from 56 north-American scientific societies, by February 2014), to be submitted to a critical number of FADOI members, in order to designate the *top ten* list.

In March 2014, a list of 32 recommendations (those most relevant for the hospital practice)

was sent to 1175 members (those affiliated to Piemonte, Veneto, Trentino AA, Friuli VG, Lazio, Campania), along with an explanatory letter, following the order of publication by Choosing Wisely®. Each member was asked to indicate the most relevant 5. The response rate was 18.1% (213, for a total number of 1037 indications) by the term of April 2014. This method was chosen in order to favor disclosure and sharing. The final *top ten* reflects the qualified opinion of a large number of FADOI members.

References

1	<ul style="list-style-type: none"> - American Society of Health System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. <i>Am J Health Syst Pharm</i> 1999;56:347-379. - Bez C, Perrottet N, Zingg T, Leung Ki EL, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. <i>Journal of Evaluation in Clinical Practice</i> 2013;19:374–378. doi: 10.1111/j.1365-2753.2012.01838.x - Gullotta R, Ferraris L, Corlezzi C, Minoli G, Prada A, Comin U, Rocca F, Ferrara A, Curzio M. Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drug? Results of a multicentre study. <i>Ital J Gastroenterol Hepatol</i> 1997;29(4):325-9. - Parnte F, Cicino C, Gallus S, Bagiggia S, Greco S, Pastore L, Bianchi Porro G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. <i>Aliment Pharmacol Ther</i> 2003;17(12):1503-6. - Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. <i>JAMA</i> 2009;301(20):2120-8. doi: 10.1001/jama.2009.722. - Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for <i>Clostridium difficile</i> diarrhoea. <i>J Hosp Infect</i> 2003;54(3):243-5.
2	<ul style="list-style-type: none"> - Infectious Disease Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. <i>Clin Infect Dis</i> 2005;40:643-665. - Société de Pathologie Infectieuse de Langue Française (SPILF) et Association française d'urologie (AFU). Infections urinaire nosocomiales de l'adulte. <i>Médecine et Maladies Infectieuses</i> 2003;33:193s-215s. - Bulfoni A, Concia E, Costantino S, Giusti M, Iori I, Mazzei T, Nardi R, Salsi A, Schito G. Orientamenti terapeutici per il trattamento delle infezioni batteriche nel paziente anziano in Medicina Interna. <i>Ital J Med</i> 2007;(1)2 Suppl: III-IV,156s-61s.
3	<ul style="list-style-type: none"> - Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. <i>Cochrane Syst Rev</i> 2009 Apr15; (2): CD007209 - Palecek EJ, Teno JM, Casarett DJ, Hanson Lc et al. Comfort feeding only: a proposal to bring clarity to decision making regarding difficulty with eating for person with advanced dementia. <i>J Am Geriatr Soc</i> 2010; 59(3): 580-584. - Hanson LC, Carey TS, Caprio AJ, LeeTJ et al Improving decision-making for feeding

	<p>options in advanced dementia: a randomized controlled trial. <i>J Am Geriatr Soc</i> 2011 Nov 59(11):2009-2016</p> <p>- Teno JM, Gozalo, PL, Mitchell SL, Does feeding tube insertion and its timing improve survival? <i>J Am Geriatr Soc</i> 2012 Oct, 60(10): 1918-21</p> <p>- Van der Steen JT, Radbruch L, MPM Hertogh C, de Boer ME, Hughes JC, Larkin P, et al. White paper defining optimal palliative care in older people with dementia: A Delphi study and recommendations from the European Association for Palliative Care. <i>Palliative Care</i> 2013;0:1-13, DOI: 10.1177/0269216313493685</p>
4	<p>- Salisbury AC, Reid KR, Alexander KP. Et al. Diagnostic blood loss from phlebotomy and hopsyial acquired anemia during acute myocardial infarction. <i>Arch Intern Med</i> 2011;171:1646-53</p> <p>- Janssens PM. Managing the demand for laboratory testing: options and opportunities. <i>Clin Chim Acta</i> 2010;411:1596-602, doi: 10.1016/j.cca.2010.07.022. Epub 2010 Jul 24.</p> <p>- http://www.roche.it/fmfiles/re7143001/ESADIA42.pdf</p>
5	<p>- Jeffrey L. Carson, MD; Brenda J. Grossman, MD, MPH; Steven Kleinman, MD; Alan T. Timmouth, MD; Marisa B. Marques, MD; Mark K. Fung, MD, PhD; John B. Holcomb, MD; Orijei Illoh, MD; Lewis J. Kaplan, MD; Louis M. Katz, MD; Sunil V. Rao, MD; John D. Roback, MD, PhD; Aryeh Shander, MD; Aaron A.R. Tobian, MD, PhD; Robert Weinstein, MD; Lisa Grace Swinton McLaughlin, MD; Benjamin Djulbegovic, MD, PhD, for the Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a critical practice guideline from tha AABB. <i>Ann Intern Med</i> 2012;157(1):49-58. doi:10.7326/0003-4819-157-1-201206190-00429.</p> <p>- Carson JL, Carless PA, Hebert P. Transfusion thresholds and other strategies for guiding allogenic red blood cell transfusion. <i>Cochrane Library</i>, DOI:10.1002/14651858.CD002042.pub3</p> <p>- Retter A, Wynol D, Pearse R, Carson D, McKennie S, Stanworth S, Allars S, Thomas D, Walsh T; British Committee for Standards ih Haematology. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. <i>Br J Haematol</i> 2013 Feb;160(4):445-64. doi: 10.1111/bjh.12143. Epub 2012 Dec 27.</p> <p>- Società Italiana di Medicina Trasfusionale e Immunoematologia (SIMTI). Raccomandazioni SIMTI sul corretto utilizzo degli emocomponenti e dei plasmaderivati. 1^AEdizione, settembre 2008. Edizioni SIMTI, Italia</p> <p>- Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. <i>N Engl J Med</i> 2014;371;1381-91</p>
6	<p>- Couto AT, Silva DT, Silvestre CC, Lyra DPJr. Quality analysis of research on the use of benzodiazepins by elderly patients in the emergency room: a systematic review. <i>Eur J Clin Pharmacol</i> 2013;60:1343-50. doi: 10.1007/s00228-012-1439-7.</p> <p>- The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Amer Geriatr Soc</i> 2012;60:616-31.</p> <p>- Finkle WD, Der JS, Greenland S, al. Risk of fractures requiring hospitalization after an initial prescription of zolpidem, alprazolam, lorazepam or diazepam in older adults. <i>J Am Geriatr Soc</i> 2011;59:1883-90.</p> <p>- Allain H, Bentue-Ferre D, Polard E, Akwa Y, Patat A. Postural instability and consequent fall and hip fractures associated with use of hypnotics in the elderly: a comparative review. <i>Drugs Aging</i> 2005;22:749-65.</p>
7	<p>- Ellershaw J, Ward C. Care of the dying patient: the last hours or days of life. <i>Brit Med J</i> 2003;326(7379):30-4.</p>

	<ul style="list-style-type: none"> - Costantini M, Ottonelli S, Canvacci L, Pellegrini F, Belcaro M. The effectiveness of the Liverpool care pathway in improving end of life care for dying cancer patients in hospital. A cluster randomized trial. BMC Health Serv Res 2011;11:13. - Lusiani L, Bordin G, Mantineo G, Roncato P, Favaro L, Tessaro L, Sandonà L, Bordin F. Cure di fine vita nei pazienti oncologici terminali in Medicina Interna. Ital J Med 2012;6:110-5. - Temel JS, Greer JA, Muzilkansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blindermann CD, Jacobsen J, Pirl WF, Billing JA, Lynch TJ. Early palliative care for patients with metastatic non-small lung cancer. N Engl J Med 2010;363:733-42.
8	<ul style="list-style-type: none"> - Dalleur O, Spinewinw A, Henrard S, Lousseau C, Speybroeck N, Boland B. Inappropriate prescribing and related hospital admission in frail older persons according to the STOPP and START criteria. Drugs Aging. 2012;29:829-37. - Schiattarella GG, Perrino C, Magliulo F, et al. Statins and the elderly: recent evidence and current indications. Aging Clin Exp Res 2012;24(S3):47-55. - Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-5. - Petersen LK, Chistensen K, Kragstrup J. Lipid lowering to the end? A review of observational studies and RCT on cholesterol and mortality in 80+ year old. Age Ageing 2010;39:674-80. - Maraldi C, Lattanzio F, Onder G, et al. Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations. Drugs Aging 2009;26(Suppl 1):41-51.
9	<ul style="list-style-type: none"> - http://www.kidney.org/professionals/KDOQI/guidelines_ckd. - http://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf - http://pathways.nice.org.uk/pathways/chronic-heart-failure - Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a board panel of rheumatologists in the 3e Initiative. Rheumatology 2012; 51:1416-1425.
10	<ul style="list-style-type: none"> - Minamimoto R, Senda M, Terauchi T et al. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann Nucl Med 2011;25:45-54 - Lee JW, Kang KW, Paeng JC, et al. Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med 2009;23:685-691.

	INDICATOR OF PERFORMANCE	INDICATOR OF OUTCOME
1	Number of prescriptions of PPI in hospital (acute phase) and outside hospital (chronic phase)	Number of hospital admissions for gastric bleeding
2	Number of prescriptions of antibiotics currently used for urinary tract infections	Number of hospital admissions for relapsing urinary infections or pyelonephritis
3	Number of prescriptions of percutaneous feeding tubes	Number of hospital admissions for aspiration pneumonias
4	Volume of laboratory requests	Length of stay in hospital and number of re-admission in hospital for the same reason in the short term
5	Blood consumption	Length of stay in hospital for heart failure (ICD9.CM 428) and number of re-admission in hospital for the same diagnosis in the short term
6	Number of prescriptions of benzodiazepines in hospital	Number of falls in hospitalized patients
7	Number of hi-tech diagnostic procedures (<i>i.e.</i> , CT or invasive procedures) during the last days of the patients who dye in hospital	Pain control during the last days of the patients who dye in hospital
8	Number of prescriptions of statins	Cardiovascular events in the elderly
9	Number of prescriptions of NSAID	Pain control
10	Number of PET/CT for cancer screening	Incidence of treatable cancers